A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

104

Participants

Timeline

Start Date

November 1, 2023

Primary Completion Date

November 1, 2024

Study Completion Date

November 1, 2026

Conditions

Hepatocellular Carcinoma

Interventions

DRUG

Sintilimab

IV infusion of Sintilimab （200mg intravenously every 3 weeks for a total of 18 cycles or tumour recurrence）

DRUG

Lenvatinib

8mg orally once a day for 1 year

PROCEDURE

Transarterial Chemoembolization (TACE)

One cycle of TACE postoperatively

Trial Locations (1)

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

All Listed Sponsors

lead

Tongji Hospital

OTHER